Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs

Table 4 Univariate and Multivariate Cox regression analyses for PFS in Cavitary and Noncavitary Adenocarcinoma patients with EGFR mutations

Variables	Univariate Analysis		Multivariate Analysis
Variables	HR (95% CI)	P	HR (95% CI)	P
Noncavity vs. Cavity	0.478 (0.271–0.843)	0.011	0.485 (0.261–0.902)	0.022
Female vs. Male	0.846 (0.635–1.127)	0.252	0.793 (0.528–1.190)	0.263
Age > 65 y vs. ≤ 65y	0.790 (0.587–1.062)	0.118	0.691 (0.489–0.976)	0.036
ECOG PS > 1 vs. 0 or 1	0.841 (0.651–1.086)	0.183	0.921 (0.674–1.259)	0.605
Smokers vs. non-smokers	1.124 (0.794–1.591)	0.511	0.919 (0.571–1.480)	0.728
TNM Stage IV vs. stage III + Recurrent	1.022 (0.901–1.160)	0.731	0.972 (0.842–1.122)	0.698
Other EGFR-TKIs^a vs. Gefitinib	0.898 (0.666–1.212)	0.483	0.806 (0.574–1.132)	0.214
Tumor size: > 5 cm vs. ≤5 cm	1.886 (1.282–2.775)	0.001	1.741 (1.158–2.619)	0.008
EGFR mutation
Exon 19 deletion	1.000 (reference)		1.000 (reference)
L858R mutation	1.564 (0.988–2.477)	0.056	1.133 (0.659–1.949)	0.651
Rare mutations^b	1.339 (0.843–2.127)	0.217	1.140 (0.674–1.928)	0.626

Abbreviations: EGFR-TKI epidermal growth factor receptor- tyrosine kinase inhibitor, PFS progression-free survival, HR hazard ratio, CI confidence interval, ECOG PS Eastern Corporation Oncology Group performance status
^aIncluding erlotinib, icotinib, afatinib (1 patient), AZD9291 (1 patient)
^bincluding EGFR mutations in exons 18 and 20, other than 19DEL and L858R mutations

ISSN: 1471-2407